FLT3 and acute myeloid leukemia: Because both the NCCN and ELN 2017 guidelines support prompt, comprehensive FLT3 testing for all patients with AML [4, 5], use of a rapid FLT3-ITD diagnostic assay has the potential to improve patient care by identifying patients with AML with a poor prognosis and allowing early intervention with FLT3-ITD targeted therapies [9–11].